Scenesse is a slow release formulation. The active drug Afamelanotide (patented in 1981) is a synthetic version of alpha-melanocyte-stimulating hormone (aMSH) which occurs naturally in the human body. They are not the same.
In case you aren't aware CUV is the failed tanning cream company Epitan renamed. Some of the patents go back as far as 2003 Most of the patents were lodged before 2010. The patents are now being extended (short term) by 'evergreening ' (creating a new use or formulation). https://patents.google.com/?assignee=clinuvel&oq=clinuvel
CUV cannot sue anybody for selling an Afamelanotide formulation where the delivery system is longer patent protected. eg transdermal creams after 2023.
A cynic might suggest CUV is desperately rushing to make as much money as possible before the golden goose gets the hatchet.
CUV Price at posting:
$29.49 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)